Type to search

mic MHRA Grants Marketing Authorisation for Novartis’ Radioligand Therapy Pluvicto®▼ (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain | Pharmtech Focus
Novartis Awarded Promising Innovative Medicine Designation for Targeted Radioligand Theragnostics in Prostate Cancer | Pharmtech Focus